Ionis Pharmaceuticals Says Data Readout From Pelacarsen Study Is Delayed

MT Newswires Live02-01

Ionis Pharmaceuticals (IONS) said results from a late-stage study of pelacarsen are expected in H1 2026 after a data readout from the phase 3 trial had been expected from drug development partner Novartis (NVS) this year.

"This update is based on the accrual rate of blinded events in the ongoing Phase 3 Lp(a)HORIZON

event-driven cardiovascular outcomes study that Novartis is conducting in more than 8,000 patients," Ionis said Friday in a statement.

Ionis said the companies expect to seek regulatory approval of the medicine in H2 2026.

"Ionis remains confident in pelacarsen and the Lp(a)HORIZON study and its potential to show benefit in patients with cardiovascular disease and high Lp(a)," according to the statement.

Ionis licensed the drug to Novartis in 2019.

Ionis shares fell 0.8% recent Friday trading, and Novartis rose 0.3%.

Price: 33.06, Change: -0.26, Percent Change: -0.77

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2508950995?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-01 02:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2508950995","market":"us","top_or_hot":-1,"title":"Ionis Pharmaceuticals Says Data Readout From Pelacarsen Study Is Delayed","media":"MT Newswires Live","content":"<html><body><p> Ionis Pharmaceuticals (IONS) said results from a late-stage study of pelacarsen are expected in H1 2026 after a data readout from the phase 3 trial had been expected from drug development partner Novartis (NVS) this year.</p><p>\"This update is based on the accrual rate of blinded events in the ongoing Phase 3 Lp(a)HORIZON</p><p>event-driven cardiovascular outcomes study that Novartis is conducting in more than 8,000 patients,\" Ionis said Friday in a statement.</p><p>Ionis said the companies expect to seek regulatory approval of the medicine in H2 2026.</p><p>\"Ionis remains confident in pelacarsen and the Lp(a)HORIZON study and its potential to show benefit in patients with cardiovascular disease and high Lp(a),\" according to the statement.</p><p>Ionis licensed the drug to Novartis in 2019.</p><p>Ionis shares fell 0.8% recent Friday trading, and Novartis rose 0.3%.</p><p>Price: 33.06, Change: -0.26, Percent Change: -0.77</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ionis Pharmaceuticals Says Data Readout From Pelacarsen Study Is Delayed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIonis Pharmaceuticals Says Data Readout From Pelacarsen Study Is Delayed\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-01 02:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ionis Pharmaceuticals (IONS) said results from a late-stage study of pelacarsen are expected in H1 2026 after a data readout from the phase 3 trial had been expected from drug development partner ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B4R5TH58.HKD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2508950995","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2508950995","pubTimestamp":1738347360,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ionis Pharmaceuticals  said results from a late-stage study of pelacarsen are expected in H1 2026 after a data readout from the phase 3 trial had been expected from drug development partner Novartis  this year.\"This update is based on the accrual rate of blinded events in the ongoing Phase 3 LpHORIZONevent-driven cardiovascular outcomes study that Novartis is conducting in more than 8,000 patients,\" Ionis said Friday in a statement.Ionis said the companies expect to seek regulatory approval of the medicine in H2 2026.\"Ionis remains confident in pelacarsen and the LpHORIZON study and its potential to show benefit in patients with cardiovascular disease and high Lp,\" according to the statement.Ionis licensed the drug to Novartis in 2019.Ionis shares fell 0.8% recent Friday trading, and Novartis rose 0.3%.Price: 33.06, Change: -0.26, Percent Change: -0.77","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4139":"生物科技","BK4588":"碎股","BK4007":"制药","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IONS":"Ionis Pharmaceuticals, Inc","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4532":"文艺复兴科技持仓","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4578":"CAR-T","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","NVS":"诺华","BK4585":"ETF&股票定投概念"},"translate_title":"Ionis Pharmaceuticals表示Pelacarsen研究的数据读取被推迟","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IONS":1,"NVS":0.9},"content_text":"Ionis Pharmaceuticals (IONS) said results from a late-stage study of pelacarsen are expected in H1 2026 after a data readout from the phase 3 trial had been expected from drug development partner Novartis (NVS) this year.\"This update is based on the accrual rate of blinded events in the ongoing Phase 3 Lp(a)HORIZONevent-driven cardiovascular outcomes study that Novartis is conducting in more than 8,000 patients,\" Ionis said Friday in a statement.Ionis said the companies expect to seek regulatory approval of the medicine in H2 2026.\"Ionis remains confident in pelacarsen and the Lp(a)HORIZON study and its potential to show benefit in patients with cardiovascular disease and high Lp(a),\" according to the statement.Ionis licensed the drug to Novartis in 2019.Ionis shares fell 0.8% recent Friday trading, and Novartis rose 0.3%.Price: 33.06, Change: -0.26, Percent Change: -0.77","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2508950995"}